Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186409403> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3186409403 endingPage "e35" @default.
- W3186409403 startingPage "e35" @default.
- W3186409403 abstract "Introduction: The coronavirus disease (COVID-19) became a global pandemic in 2019. Some studies have shown that the virus can cause a higher mortality in people with weakened immune systems, such as the elderly, those taking immunosuppressive drugs, and those with underlying disorders, than in the general population. Objectives: The aim of this study was to evaluate the prevalence of COVID-19 in patients with rheumatic disorders who received biologic disease-modifying antirheumatic drugs (DMARDs). The effect of precautionary self-isolation in these patients was also determined. Patients and Methods: This descriptive study involved 200 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) who were treated with biologic DMARDs. Patients with symptoms of the coronavirus infection were invited to have a COVID-19 test that involved a COVID-19 IgG antibody test or a polymerase chain reaction (PCR) test (i.e., nasal swab). Additionally, patients were asked about their precautionary self-isolation status during this period. Results: The mean age of the patients was 51.29 years ± 13.38 years. The ratio of males to females was 27 to 173. Of the 200 patients included in the study, 156 (78%) had RA, 10 (5%) had SLE, and 34 (17%) had MS. Seventy-five percent of the patients used rituximab. Ten patients (5%) were symptomatic of COVID-19, although only four patients had a definitive diagnosis of the disease. All patients who were symptomatic of COVID-19 took rituximab. Ten percent of patients who did not observe the precautionary self-isolation period were diagnosed with COVID-19. Conclusion: Patients who receive biologic DMARDs have a lower risk of developing COVID-19 and a lower risk of mortality from the disease than the general population." @default.
- W3186409403 created "2021-08-02" @default.
- W3186409403 creator A5021467953 @default.
- W3186409403 creator A5046207802 @default.
- W3186409403 creator A5061797435 @default.
- W3186409403 creator A5076369814 @default.
- W3186409403 creator A5081236313 @default.
- W3186409403 creator A5089327132 @default.
- W3186409403 date "2021-06-21" @default.
- W3186409403 modified "2023-09-26" @default.
- W3186409403 title "The prevalence of COVID-19 in patients with rheumatoid arthritis, multiple sclerosis, or systemic lupus erythematosus receiving biologic disease-modifying antirheumatic drugs" @default.
- W3186409403 doi "https://doi.org/10.34172/ipp.2021.35" @default.
- W3186409403 hasPublicationYear "2021" @default.
- W3186409403 type Work @default.
- W3186409403 sameAs 3186409403 @default.
- W3186409403 citedByCount "0" @default.
- W3186409403 crossrefType "journal-article" @default.
- W3186409403 hasAuthorship W3186409403A5021467953 @default.
- W3186409403 hasAuthorship W3186409403A5046207802 @default.
- W3186409403 hasAuthorship W3186409403A5061797435 @default.
- W3186409403 hasAuthorship W3186409403A5076369814 @default.
- W3186409403 hasAuthorship W3186409403A5081236313 @default.
- W3186409403 hasAuthorship W3186409403A5089327132 @default.
- W3186409403 hasBestOaLocation W31864094031 @default.
- W3186409403 hasConcept C126322002 @default.
- W3186409403 hasConcept C198451711 @default.
- W3186409403 hasConcept C203014093 @default.
- W3186409403 hasConcept C2777575956 @default.
- W3186409403 hasConcept C2779123688 @default.
- W3186409403 hasConcept C2779134260 @default.
- W3186409403 hasConcept C2779338263 @default.
- W3186409403 hasConcept C2780653079 @default.
- W3186409403 hasConcept C2908647359 @default.
- W3186409403 hasConcept C3008058167 @default.
- W3186409403 hasConcept C524204448 @default.
- W3186409403 hasConcept C71924100 @default.
- W3186409403 hasConcept C99454951 @default.
- W3186409403 hasConceptScore W3186409403C126322002 @default.
- W3186409403 hasConceptScore W3186409403C198451711 @default.
- W3186409403 hasConceptScore W3186409403C203014093 @default.
- W3186409403 hasConceptScore W3186409403C2777575956 @default.
- W3186409403 hasConceptScore W3186409403C2779123688 @default.
- W3186409403 hasConceptScore W3186409403C2779134260 @default.
- W3186409403 hasConceptScore W3186409403C2779338263 @default.
- W3186409403 hasConceptScore W3186409403C2780653079 @default.
- W3186409403 hasConceptScore W3186409403C2908647359 @default.
- W3186409403 hasConceptScore W3186409403C3008058167 @default.
- W3186409403 hasConceptScore W3186409403C524204448 @default.
- W3186409403 hasConceptScore W3186409403C71924100 @default.
- W3186409403 hasConceptScore W3186409403C99454951 @default.
- W3186409403 hasIssue "2" @default.
- W3186409403 hasLocation W31864094031 @default.
- W3186409403 hasOpenAccess W3186409403 @default.
- W3186409403 hasPrimaryLocation W31864094031 @default.
- W3186409403 hasRelatedWork W2010260295 @default.
- W3186409403 hasRelatedWork W2056867162 @default.
- W3186409403 hasRelatedWork W2091629131 @default.
- W3186409403 hasRelatedWork W2414990785 @default.
- W3186409403 hasRelatedWork W2801221612 @default.
- W3186409403 hasRelatedWork W3178040701 @default.
- W3186409403 hasRelatedWork W3211699297 @default.
- W3186409403 hasRelatedWork W4310965532 @default.
- W3186409403 hasRelatedWork W562161591 @default.
- W3186409403 hasRelatedWork W2185923697 @default.
- W3186409403 hasVolume "7" @default.
- W3186409403 isParatext "false" @default.
- W3186409403 isRetracted "false" @default.
- W3186409403 magId "3186409403" @default.
- W3186409403 workType "article" @default.